Many Wall Street investors keep a close eye on the opinions of major brokerages, such as Citigroup (NYSE: C ). Therefore, today we'll explore three promising growth stocks that have recently receiv...

It's not exactly an ideal time to be a stock market investor. The market is in correction territory, with many leading tech giants experiencing a pullback in prices.

Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.

Shares of Boston Scientific (BSX) hit an all-time high Wednesday as the maker of medical equipment reported better-than-anticipated quarterly results and boosted its guidance on demand for its card...

Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with ...

Boston Scientific (BSX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.47 per share a year ago.

Medical device maker Boston Scientific raised its annual profit forecast on Wednesday as the company banks on resilient demand for its heart devices, with post-pandemic elective surgical procedures...

Boston Scientific Corp.'s stock BSX, +1.43% rose 2.7% early Wednesday, after the medical tech company's first-quarter earnings beat analyst estimates. The company had net income of $495 million, or...

Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for...

Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.

With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.

Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.

Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.